Lynda Schneider is engaged in evaluating new therapies for allergic diseases through clinical trials. Current trials focus on evaluating a multidisciplinary approach to caring for children with atopic dermatitis (AD), exploring the genetics and phenotypes of patients with AD, and evaluating prophylactic treatments for asthma.
Through the 1990s Dr. Schneider and colleagues evaluated new treatments for atopic dermatitis, including interferon-gamma, topical tacrolimus, and pimecrolimus. They also studied the use of anti-IgE for food allergy and C1-inhibitor for hereditary angioedema. Other projects have included the use of intravenous immunoglobulin for asthma as well as anti-IgE for asthma.
Her current projects include the Study Atopic March project which evaluates early intervention for babies with atopic dermatitis to see if the development of asthma and other allergic diseases can be modified. Children's Hospital Boston has been funded by the National Institutes of Health as a site for the Atopic Dermatitis and Vaccinia Network: Clinical Studies Consortium.
About Lynda Schneider
Lynda Schneider received her MD from Jefferson Medical College. She completed an internship and residency at Massachusetts General Hospital and a postdoctoral fellowship at Children's Hospital Boston.
Dr. Schneider received the 2004 AAAAI/Aventis Women in Allergy Project Grant Award.
- Schneider LC, Baz Z, Zarcone C, Zurakowski D. Safety of long-term therapy with recombinant Interferon-gamma (rIFN-g) for atopic dermatitis (AD). Annals of Allergy, Asthma and Immunology 1998; 80: 263-268.
- Leung DYM, Sampson HA, Yunginger JW, Burks AW, Schneider LC, Wortel CH, Davis FM, Hyun JD, Shanahan WR. Effect of anti-IgE therapy in patients with peanut allergy. New England Journal of Medicine 2003; 348: 986-993.
- Alangari AA, Twarog FT, Shih MC, Schneider LC. Clinical features and anaplylaxis in children with cold urticaria. Pediatrics 2004; 113: e312-e316.